Loss of Ultragenyx Pharmaceutical on GAAP for 6 months of 2021 amounted to $258.569 million, increasing 2.8 times compared to $93.71 million in the previous year. Revenue increased 90.1% to $186.37 million from $98.018 million a year earlier.
Loss of Ultragenyx Pharmaceutical on GAAP for 6 months of 2021 amounted to $258.569 million, increasing 2.8 times compared to $93.71 million in the previous year. Revenue increased 90.1% to $186.37 million from $98.018 million a year earlier. 
ir.ultragenyx.com
English (US) 